Merck snags Chinese obesity drug in nearly $2 billion deal
Merck will gain the exclusive global license for Chinese drugmaker Hansoh’s HS-10535, an experimental oral drug that targets GLP-1 receptors.
Dante Ulanday - News Moderator 
Merck will gain the exclusive global license for Chinese drugmaker Hansoh’s HS-10535, an experimental oral drug that targets GLP-1 receptors. Read More
:quality(85):upscale()/2025/02/27/808/n/1922398/26784cf967c0adcd4c0950.54527747_.jpg)
